You are leaving and being redirected to www.sanofi.us, our parent company, where all product inquiries are handled.

1-877-4MOZOBIL
(1-877-466-9624)

Patients and Families

Mozobil (plerixafor injection) is approved by the United States Food and Drug Administration (FDA) to be used with another agent, granulocyte-colony stimulating factor (G-CSF), to mobilize hematopoietic stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).

Autologous Stem Cell Transplant

If you use your own stem cells in a transplant, it is referred to as an autologous stem cell transplant. Mozobil in combination with G-CSF is used in patients with NHL or MM undergoing an autologous stem cell transplant.

Learning More

HSCT can be a complicated process. If your doctor has recommended an autologous stem cell transplant for you or your family member it may be helpful to know what to expect as you prepare for this process.

This website describes what an autologous stem cell transplant is and provides information on Mozobil and the process associated with autologous transplantation. It also describes the preparation you may undergo before an autologous transplant. We hope the website may help address some of your questions and provide useful information.

The information on this website is not intended to replace the information provided by your doctor or healthcare provider nor is it a substitute for the discussions you should have with your transplant team.

Questions to Ask Your Doctor

Prepare for your next appointment with our list of questions to ask your doctor.

Download our Patient and Caregiver Education Booklet (PDF)

Autologous Stem Cell Transplant Process

View our guide to learn more about the autologous stem cell transplant process.
Download guide

Indication

Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

Important Safety Information

Mozobil is not intended for HSCT mobilization and collection in patients with leukemia.
Mozobil in combination with G-CSF increases circulating WBCs. Your WBC counts will be monitored.
Thrombocytopenia (a decrease in the number of platelets circulating in the blood) has been observed in patients receiving Mozobil. Your platelet counts will be monitored.
Cancer cells may be released from the bone marrow and subsequently collected along with your stem cells during apheresis. The potential effects of infusing cancer cells during your transplant have not been well-studied.
Your spleen may be examined if you experience pain in the left upper stomach area or left shoulder area as these may be signs of an enlarged or burst (ruptured) spleen.
Mozobil may harm the unborn child when administered to a pregnant woman. Scientific studies have shown that Mozobil caused harm to unborn animals. The safety of Mozobil in pregnant women has not been established in clinical trials. If you are of childbearing potential you should be advised to avoid becoming pregnant while receiving treatment with Mozobil. If this drug is used during pregnancy, or if you become pregnant while taking this drug, you should be apprised of the potential hazard to the unborn child.
The most common adverse reactions (occurring in greater than or equal to 10% of patients) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), tiredness (fatigue) (27%), injection site reaction (34%), headache (22%), pain in your joints (arthralgia) (13%), dizziness (11%), and vomiting (10%).